home / stock / ghrs / ghrs news


GHRS News and Press, GH Research PLC From 12/19/23

Stock Information

Company Name: GH Research PLC
Stock Symbol: GHRS
Market: NASDAQ
Website: ghres.com

Menu

GHRS GHRS Quote GHRS Short GHRS News GHRS Articles GHRS Message Board
Get GHRS Alerts

News, Short Squeeze, Breakout and More Instantly...

GHRS - CVAC, REE and NEON among mid-day movers

2023-12-19 12:49:04 ET Gainers: Panbela Therapeutics ( PBLA ) +54% . Singlepoint ( SING ) +41% . MedAvail Holdings ( MDVL ) +32% . REE Automotive Ltd ( REE ) +29% . Pulse Biosciences ( PLSE ) +28% . Neonode ( NEON ) +25...

GHRS - Gh Research Plc ($GHRS) Trading Report

2023-12-11 02:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

GHRS - GH Research GAAP EPS of -$0.11

2023-11-10 08:02:21 ET More on GH Research Seeking Alpha’s Quant Rating on GH Research Historical earnings data for GH Research Financial information for GH Research For further details see: GH Research GAAP EPS of -$0.11

GHRS - GH Research Reports Third Quarter Financial Results and Provides Business Updates

DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and pro...

GHRS - Expected US Company Earnings on Thursday, November 9th, 2023

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

GHRS - Expected earnings - GH Research PLC

GH Research PLC (GHRS) is expected to report $-0.2 for Q3 2023

GHRS - GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical development program for GH001, its ...

GHRS - With ecstasy a potential PTSD therapy, psychedelic treatments could take off

2023-09-16 16:00:56 ET On Sept. 14, the Multidisciplinary Association for Psychedelic Studies ("MAPS") announced positive results on a second phase 3 trial for MDMA -- also known as ecstasy -- for post-traumatic stress disorder that were published in a scientific journal. The data in th...

GHRS - Psilocybin in depression: study shows lasting benefit

2023-08-31 12:35:49 ET More on psychedelic drugmakers Compass Pathways: Debt Deal Secured, Cash Runway Extended COMPASS Pathways plc ( CMPS ) Q2 2023 Earnings Call Transcript Mind Medicine Inc. ( MNMD ) Q2 2023 Earnings Call Transcript Psychedelic Sto...

GHRS - GH Research Non-GAAP EPS of -$0.15

2023-08-23 15:24:11 ET GH Research press release ( NASDAQ: GHRS ): Q2 Non-GAAP EPS of -$0.15. Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023. For further details see: GH Research Non-GAAP EPS of -$...

Previous 10 Next 10